Common side effects of Inavolisib and how to deal with them

Inavolisib (Inavolisib), as a selective inhibitor of PI3Kα, has shown controllable safety in clinical application, but it may still cause certain side effects, which requires high attention from breast cancer patients and medical teams. Common adverse reactions mainly include digestive system symptoms, hematological abnormalities, rash, fatigue, and electrolyte changes. Patients may experience mild nausea, diarrhea, or loss of appetite in the early stages of treatment. These symptoms can usually be relieved by adjusting diet and taking medication in divided doses.

In terms of hematological abnormalities, some patients may experience a mild decrease in neutrophils or platelets. Therefore, regular blood routine monitoring is required during treatment to detect and intervene in potential risks in a timely manner. For rashes or mild allergic reactions, patients are advised to keep their skin clean, use mild skin care products, and use anti-allergic drugs for symptomatic treatment under the guidance of a physician. Fatigue and mild headaches are common and can be improved by ensuring adequate rest, moderate exercise and reasonable medication use.

In the case of combined use of palbociclib and fulvestrant, drug interactions may occur, and the dosage and dosage interval prescribed by the physician need to be strictly followed. In the event of persistent or severe side effects, the patient should be reported to the medical team promptly to assess whether dosage adjustment or temporary discontinuation is needed. Overseas guidelines emphasize that early identification and standardized treatment of side effects can effectively ensure efficacy while reducing the risk of treatment interruption. Through individualized monitoring, timely intervention and educational guidance, the vast majority of adverse reactions can be effectively managed.

Overall, the side effects of inaliset are controllable and can be alleviated through standard monitoring and symptomatic treatment. Patients should maintain close communication with their doctors during treatment, follow the follow-up plan, and conduct regular laboratory tests and symptom assessments to ensure the safety and sustainability of the combination therapy and maximize the efficacy of the precise targeting strategy in endocrine-resistant breast cancer.

Reference materials:https://www.itovebi-hcp.com/